International Society for Bipolar Disorders Regional Group Conference 2004

Session Details

Poster Session

Friday, 6 February 2004 16:30 -18:00

Mood Disorders after Mild Traumatic Brain Injuries
  • Raymond J Ancill, private psychiatric practice, Canada
    • Analysis of Treatment-Emergent Mania with Olanzapine/Fluoxetine Combination
  • Dr Sara A Corya, Lilly Research Laboratories, United States
    • Olanzapine/Fluoxetine Combination in the Treatment of Rapid-Cycling Bipolar Depression
  • Dr Sara A Corya, Lilly Research Laboratories, United States
    • Demographic and Clinical Characteristics of the Hospitalized Patients with Bipolar Disorders at a University Hospital in Korea: 1990-2001
  • Kyoo-Seob Ha, Seoul National University Bundang Hospital, Korea
    • Add-on Quetiapine For Patients With Bipolar Disorder: Case Series
  • Roumen V Milev, PCCC, Mental Health Services, Canada
    • Bipolar Comprehensive Outcomes Study (BCOS): An Australian Observational Study of the Treatment and Outcome of Patients with Bipolar Disorder
  • Dr Michael Berk, The University of Melbourne, Australia
    • Olanzapine's Efficacy for Relapse Prevention in Bipolar Disorder: A Randomized Double-Blind Placebo-Controlled 12-Month Clinical Trial
  • Dr Mauricio Tohen, Lilly Research Laboratories, United States
    • Role of Olanzapine in the Prophylaxis of Peurperal Psychosis
  • Verinder Sharma, Regional Mental Health Care London, Canada
    • Open-Label Maintenance Treatment for Bipolar Depression Using Olanzapine or Olanzapine/Fluoxetine Combination
  • Dr Maurico Tohen, Lilly Research Laboratories, United States
    • Olanzapine in the Relapse Prevention of Bipolar Disorder Based on DSM-IV Syndromic Criteria
  • Dr Mauricio Tohen, Lilly Research Laboratories and Harvard Medical School/McLean Hospital, United States
    • Open-Label Use of Lamotrigine Maintenance Treatment in Bipolar Depression: Combination Therapy Experience
  • Dr Philip Mitchell, University of New South Wales, Australia
    • The Effects of Lithium and Lamotrigine in Prevention of Relapse/Recurrence of Bipolar I Depression
  • Dr Lakshmi Yatham, The University of British Columbia, United States
    • Burden of Manic vs Depressive Symptoms in Subjects with Bipolar Disorder
  • Dr Mark Frye, University of California at Los Angeles, United States
    • Manic Switch Rates and Possible Risk Factors: Five-Year Retrospective Evaluation From A University Clinic
  • Prof Simavi Vahip, Ege University School of Medicine, Turkey
    • Neuro Cognitive Functions in Remitted Patients of Bipolar I Disorder
  • Prof Jitendra K Trivedi, C.S.M.Medical University (upgraded King George's Medical College ),, India
    • The Daily-life Creativity and Bipolar Disorders: A Study in a Brazilian Sample of Patients, Their Relatives and Normal Controls
  • MD, MSc Flávio M Shansis, Hospital de Clínicas de Porto Alegre/ Dep. Bioquímica UFRGS, Brazil
    • Olanzapine Treatment in Juvenile Lithium Resistant Manic Patients
  • Saeed Momtazi, Zanjan Medical University, Iran
    • Bipolar-panic Comorbidity within Bipolar Families: A study of Siblings
  • Dr Carolyn J Doughty, Christchurch School of Medicine and Health Sciences, University of Otago, New Zealand
    • Neuropsychological Deficits Observed During the Illness Episode Persist in Euthymia
  • Prof Judith Jaeger, The Zucker Hillside Hospital and Albert Einstein College of Medicine, United States
    • The Association Between Interpersonal Social Characteristics of P.T.S.D Patients with Mental Disorder severity in Isfahan
  • Mahmoud Nasiri, Isfahan University, Iran
    • Add-on Therapy of Risperidone in Combination with Mood Stabilizers in Bipolar Mania
  • Professor Won-Myong Bahk, The Catholic University of Korea College of Medicine, Korea
    • P50 Supression Study in a Sample of Type I Euthymic Bipolar Patients, Their Relatives and Normal Controls: A Trace or a State Condition?
  • MD, MSc Flávio M Shansis, Hospital de Clínicas de Porto Alegre/ Dep. Bioquímica UFRGS, Brazil
    • Growth Hormone Response to Zolmitriptan in Acute Manic Patients
  • Dr I-Shin Shiah, Tri-Service General Hospital, Taiwan
    • Inositol, the Missing Link in Understanding the Pathophysiology of Bipolar Affective Disorder
  • Prof Amarendra N Singh, Queen's University, Hotel Dieu Hospital, Canada
    • Effects of Lamotrigine on Quality of Life in Patients with Bipolar I disorder
  • Anupama A Krishnan, GlaxoSmithKline, United States
  • Gary Evoniuk, GlaxoSmithkline, United States
    • Effects of Lamotrigine on Neurocognitive Measures in Bipolar I Patients
  • Dr Lakshmi N Yatham, The University of British Columbia, Canada
    • Lamotrigine and Lithium as Maintenance Treatment for Bipolar I Disorder
  • Dr Lakshmi Yatham, The Univeristy of British Columbia, Canada
    • Lamotrigine Controls Bipolar Depression without Destabilizing Mood
  • Dr Michael Berk, The University of Melbourne, Australia
    • Safety and Tolerability of Lamotrigine in Bipolar I Disorder
  • Professor Eduard Vieta, Hospital Clinic, University of Barcelona, Spain
    • Effects of Lithium and Lamotrigine Prophylaxis on Body Weight in Patients with Bipolar I Disorder
  • Dr Charles Bowden, University of Texas Health Science Center, United States
    • Topiramate and Sibutramine in the Treatment of Psychotropic Drug-induced Obesity
  • Nane C Biedermann, Universitätsklinik für Psychiatrie und Psychosomatik Freiburg, Germany
    • A Trend of Drug Use in Inpatients with Bipolar I Disorder ; 4-year Naturalistic Study
  • Won-Myong Bahk, The Catholic University of Korea College of Medicine, Korea
    • Lamotrigine as Effective Treatment in Young People with Bipolar Affective Disorder
  • Penelope Maxwell, Child and Adolescent Mental Health - Nexus, Australia
    • Bipolar Patients' Satisfaction and Acceptability of Long-term Adjunctive Therapy with Gabapentin
  • Ahmad Imam, Kharkiv Medical Academy of Postgraduate Education, Ukraine
  • Dr Felix S Otusile, Kharkiv State Medical University, Ukraine
  • Dr Victor Soldatkin, Rostov-on-don State Medical University, Russia
    • Concomitant use of Lamotrigine with Lithium or Valproate in Bipolar I Disorder
  • Dr Charles Bowden, University of Texas Health Science Center, United States
    • Pharmacokinetic Interaction and Tolerability of Lamotrigine and Olanzapine Co-administration in Healthy Volunteers
  • Gary Evoniuk, GlaxoSmithkline, United States
    • EEG Abnormalities Associated with Antipsychotics: A Comparison of Quetiapine, Olanzapine, Haloperidol and Healthy Subjects
  • Dr Benedikt L Amann, Department of Psychiatry LMU Munich, Germany
    • Responsible Factors for Relapses, Reoccurrences and Refractoriness in the Management of Bipolar Affective Disorder
  • Prof Amarendra N Singh, Queen's University, Hotel Dieu Hospital, Canada
    • Olanzapine in the Treatment of Rapid-Cycling Bipolar Disorders: An Open Prospective Study
  • Dr Russell D'Souza, Mental Health Research Institute, Australia
  • Prof Nicholas Keks, Mental Health Research Institute, Australia
    • An Open Label Study of Quietapine in the Treatment of Rural Patients with Bipolar Disorder and Amphetamine Abuse
  • Dr Russell D'Souza, Mental Health Research Institute, Australia
    • A Case Control Study in the Use of Telemedicine for Treatment Adherence and Improved Outcomes in Rural Patients with Bipolar Disorder
  • Dr Russell D'Souza, Mental Health Research Institute, Australia
    • A Study of the Prevalence of Interepisodal Symptoms Including Demoralisation in Bipolar Patients Being Managed in Maintenance Phase of the Illness
  • Dr Russell D'Souza, Mental Health Research Institute, Australia
    • Characterizing Suicidal Behavior in Comorbid Bipolar Disorder and Alcoholism
  • Ihsan M Salloum, Western Psychiatric Institute and Clinic of the University of Pittsburgh Medical Center, United States
    • Switching to Quetiapine in Patients with Acute Mania who Were Intolerant of Risperidone
  • Chi-Un Pae, The Catholic University of Korea College of Medicine, Korea
    • Combination of Mood Stabilizer with Quetiapine for Treatment of Acute Bipolar Disorder: An Open Label Study
  • Won-Myong Bahk, The Catholic University of Korea College of Medicine, Korea
    • Aripiprazole in Acute Mania: Results from a Second Placebo-Controlled Study
  • William J Hadjakis, Bristol Myers Squibb Pharmaceutical, Australia
    • Safety and Tolerability of Aripiprazole Versus Placebo in Acute Mania: A Pooled Data Analysis
  • Elizabeth Hale, Bristol-Myers Squibb Pharmaceutical, Australia
    • Baseline Characteristics of a Bipolar Manic Patient Group Enrolled in a 1-year Observational Study of Health Outcomes in Turkey
  • Temel Seker, Turkey
    • Which is the Best Mania Rating Scale? A Comparative Study of Psychometric Properties of Young, CARS-M and Bech-Rafaelsen Scales
  • MD, MSc Flávio M Shansis, Hospital de Clínicas de Porto Alegre/ Dep. Bioquímica UFRGS, Brazil
    • Zotepine Loading in Acute and Severely Manic Patients: A Pilot Study
  • Dr Benedikt L Amann, Dep. of Psychiatry, LMU Munich, Germany
    • Quetiapine Adjunctive Therapy for Acute Mania Associated With Bipolar Disorder
  • J Mullen, AstraZeneca, United States
    • Quetiapine Monotherapy for the Treatment of Mania
  • M Brecher, AstraZenenca, United States
    • Randomized, Double-blind, Controlled Data on the Treatment of Mania With Quetiapine
  • M Jones, AstraZeneca, United States
    • Quetiapine for the Treatment of Mania in Bipolar Disorder: A Randomized Controlled Trial
  • B Paulsson, AstraZeneca, Sweden
    • Open-Label Pharmacokinetic Study of Quetiapine Plus Divalproex in Patients With Schizophrenic/Schizoaffective Disorders or Bipolar Disorder
  • CL DeVane, Institute of Psychiatry, Medical University of South Carolina, United States